TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02255526

Intervention type: DEVICE
Intervention: BodyGuardian
Description: BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG

Intervention type: DEVICE
Intervention: BodyGuardian
Description: BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
Study: NCT00832650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: 8 mg OD for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: OD for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Description: 10 mg OD for 14 days
Study: NCT02814461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib (dose escalation): for total 8 weeks during and after RT, with starting dose of 1mg BID. According to the rule of traditional 3 + 3 design, 3-level axitinib dose escalation will be conducted: 1mg BID (level - I), 2mg BID (level - II) and 3mg BID (level - III).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy (RT) dose (fixed strength for normal liver): 37.5 to 67.5 Gy in 15 fractions (2.5 to 4.5 Gy per fraction) to liver tumor(s) (e.g. portal vein thrombosis, tumors with size ≥3 cm, or recurrent/refractory tumors). The final prescribed dose is based on an upper limit of mean liver dose of 18 Gy for all plans. (Daily Entecavir 0.5-1mg or Telbivudine 600mg is recommended for patients with positive hepatitis B during and 3 months after RT.)
Study: NCT00958633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram will be prescribed in the dose range 10-30 mg daily.~* In patients randomized to the 8-week group, escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~* The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin XL
Description: Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~* In patients randomized to the 8-week group, bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~* The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points.
Study: NCT01205269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683, 200 mcg
Description: Dry powder for inhalation, single dose
Study: NCT02738918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nulojix (Belatacept)
Description: Nulojix Administration will start the day of transplantation (day 1 and first dosing day);10 mg/kg : (day1, 5,14,28 ), Week 8 and 12 and then 5 mg/kg every 4 weeks until Month 12
Study: NCT00854386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restrictive fluid administration
Description: Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
Study: NCT02365818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CG0070
Study: NCT01211496

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-speed power training
Description: High speed resistance training, 3 sessions per week for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Slow-speed strength training
Description: Slow speed resistance training, 3 sessions per week for 12 weeks
Study: NCT02354352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
Study: NCT01838278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vojta Physiotherapy Method
Description: Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
Study: NCT04557150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. Forimtamig will be administered as per the dosing schedule defined in Part I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. Forimtamig will be administered as per the dosing schedule defined in Part I.
Study: NCT03927742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shade + app with messaging
Description: Shade wearable device and application with UV messaging activated
Study: NCT00438932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Lanthanum carbonate 1000mg 3x/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Lanthanum carbonate 1000mg 3x/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Phosphorus Diet
Description: Low phosphorus diet will consist of 800 mg of phosphorus per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Phosphorus Diet
Description: Low phosphorus diet will consist of 800 mg of phosphorus per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unrestricted Phosphorus Diet
Description: Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unrestricted Phosphorus Diet
Description: Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Lanthanum Carbonate placebo given three times a day with meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Lanthanum Carbonate placebo given three times a day with meals.
Study: NCT03203005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA970A plus CV8102 and Cyclophosphamide
Description: Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms \[µg\] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months.
Study: NCT04098159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: duplex ultrasound
Description: regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion
Study: NCT00710060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Popular Opinion Leader (C-POL)
Description: The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/STD educational materials
Description: Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV/STD educational materials
Description: Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
Study: NCT00203931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study: NCT02255734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Study: NCT00500695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing
Study: NCT04069273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Monotherapy
Description: Pembrolizumab 200 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Monotherapy
Description: Pembrolizumab 200 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 10 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 10 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV
Study: NCT00500695

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation
Study: NCT05674266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AN Active tDCS
Description: The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AN Sham tDCS
Description: The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
Study: NCT01194115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cephalexin & metronidazole
Description: cephalexin at 500 mg per oral every 8 hours for a total of 6 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo representing standard of care
Study: NCT03197493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa 25-100 mg
Description: High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa 25-100 mg
Description: High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
Study: NCT03931577

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C-reactive protein rapid testing
Description: Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C-reactive protein rapid testing
Description: Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Communication skill enhancement
Description: Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Communication skill enhancement
Description: Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.
Study: NCT02505932

Intervention type: PROCEDURE
Intervention: Arthroscopic Latarjet procedure
Description: arthroscopic approach (set Depuy-Mitek, Raynham, MA)

Intervention type: PROCEDURE
Intervention: Mini-open Latarjet procedure
Description: mini-open approach (set Arthrex, Naples, FL)
Study: NCT00788840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulatard
Description: Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Detemir insulin used as long-acting insulin in treatment phase of study.
Study: NCT02672904

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser
Description: surgical removal of carcinoma from the vocal cords with CO2 laser
Study: NCT01053078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
Study: NCT02672904

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KTP laser
Description: surgical removal of carcinoma from the vocal cords with KTP laser
Study: NCT01801059

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive patient activation intervention by educational video and brochure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive patient activation intervention by educational video and brochure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive patient activation intervention by educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive patient activation intervention by educational video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT00533390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: 600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: 600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
Study: NCT01053078

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 month treatment; placebo tablet once daily for 28 days
Study: NCT01866995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raylis
Description: Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raylis
Description: Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard prostatostasis therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard prostatostasis therapy
Study: NCT03927742

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape + app without messaging
Description: Shade wearable device and application without UV messaging activated
Study: NCT04949984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: BLT consisted of 30-minute morning sessions with an intensity of 10,000 lux, five days a week (Monday to Friday), for 4 weeks.
Study: NCT02306434

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy by iCBT
Description: Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care-counselling
Description: Standard care (Counselling by midwives)
Study: NCT02046499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin will be administered intravenously as per standard protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin ergometrine
Description: Oxytocin ergometrine will be administered intra-musculalry
Study: NCT02757261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Low-level laser therapy administrated to acupoints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Description: Occlusal splint with expander
Study: NCT02067247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeamMed Speed-of-Sound bone strength test at forearm
Description: BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
Study: NCT04344067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Far Infrared Therapy
Description: The WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to conduct FIR therapy in this study. The electrified ceramic plates of the emitter generated electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 milliwatt (mw) /cm2 when the top radiator was set at a distance of 30 and 20 cm above the skin surface respectively.
Study: NCT00693992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT02614976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Padding
Description: Padding webrill (Covidian) TM 6
Study: NCT03697291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS wire
Description: The wiring connection used to convey ECG signal from inside the body

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS wire
Description: The wiring connection used to convey ECG signal from inside the body
Study: NCT03155750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero Time Exercise
Description: Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: We offer a 2-session education course to teach the subjects about sleep hygiene practice.
Study: NCT02473614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music Glove
Description: Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimum of 3 hours per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hand Exercise Program
Description: Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimum of 3 hours per week.
Study: NCT01600300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tesmac
Description: Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
Study: NCT02729259

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Reality Snowworld
Description: The subjects will receive Virtual Reality Snowworld during their wound care procedure. The nurse will be doing their wound care.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Reality slides of nature
Description: The subjects will receive Virtual Reality Slides of Nature during their wound care procedure. The nurse will be doing their wound care.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control standard nurse wound care
Description: The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
Study: NCT00884117

Intervention type: DRUG
Intervention: Oseltamivir
Description: Participants may receive treatment at the discretion of the investigator according to local practice standards, and there is no protocol-specified intervention. However, analyses will be presented separately for participants treated with oseltamivir during the course of the study.